FluidForm Bio

Waltham, United States Founded: 2017 • Age: 9 yrs
3D bioprinting solutions for engineered tissues are developed.

About FluidForm Bio

FluidForm Bio is a Healthcare company based in Waltham (United States) founded in 2017 by Michael Graffeo and Adam Feinberg. 3D bioprinting solutions for engineered tissues are developed. It operates in the Healthcare and Technology sectors. The company has 19 employees. Its chief executive, as recorded, is Michael Graffeo. FluidForm Bio offers products and services including FRESH 3D Bioprinting. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is FLUIDFORM, INC. Its competitors include Amyris, AskBio and Ginkgo Bioworks; 3 of its 3 listed competitors have raised funding.

Company details

FluidForm Bio was founded in 2017 and is based in Waltham, United States. 3D bioprinting solutions for engineered tissues are developed by the company within the biotechnology sector. FRESH technology is integrated with 3D printing, computational biology, synthetic biology, artificial intelligence, and advanced materials. Tissues are constructed using cells and proteins for applications in research and medical fields.

  • Headquarters Waltham, United States
  • Employees 19
  • Founders Michael Graffeo, Adam Feinberg
  • Sectors
    Healthcare
    Technology
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website fluidformbio.com
  • Social LinkedIn X
  • Legal Name Fluidform, Inc.
Key Metrics
  • Latest Funding Round
    $228.55K (USD), Grant

    Aug 2021

  • Investors
  • Employee Count
    19

Products & Services of FluidForm Bio

FluidForm Bio offers a comprehensive portfolio of products and services, including FRESH 3D Bioprinting.

FRESH 3D Bioprinting
Bioprinting Technology

Creates vascularized implantable tissues for medical treatments like diabetes.

Funding Insights of FluidForm Bio

  • Total Rounds 3
  • Last Round Grant β€” $228,550
  • First Round $255,369

    (Apr 2021)

  • Investors Count 1

All 3 funding rounds of FluidForm Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2021$228,550Grant––
May 2021$249,644Grant––
Apr 2021$255,369Grant––
Valuation history

1 investors in total: 1 institutional.

Investors in FluidForm Bio

FluidForm Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for FluidForm Bio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of FluidForm Bio

7 people are tracked at FluidForm Bio (5 in leadership, 2 in team); the tracked headcount is 19.

NameRoleGroup
Michael Graffeo
Co-Founder & CEOLeadership
Adam Feinberg
Co-Founder & CTOLeadership
Mike Graffeo
CEOLeadership
Rickey Kallicharan
Chief Business OfficerLeadership
Erik Waters
Chief Financial OfficerLeadership
Jonathan Paris
AdvisorTeam
Katelynn Russ
Sr. Biomedical EngineerTeam
Premium access

Complete people profiles for FluidForm Bio

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of FluidForm Bio

3 dated milestones of FluidForm Bio across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded FluidForm Bio is founded.
  2. Funding First funding round of $255K.
  3. Funding Latest funding round, Grant, of $229K.

Competitors of FluidForm Bio

FluidForm Bio has 3 listed competitors in our database, 3 of them funded. They include Amyris, AskBio and Ginkgo Bioworks.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
amyris.com2003Emeryville, United States$487.2M747
Developer of renewable products for industrial solutions
askbio.com2001Durham, United States$235M
Gene and protein therapies are developed for treating various diseases.
ginkgobioworks.com2008Boston, United States$795.75M1,218
Gene editing-based cultured ingredients are provided for agriculture.
Premium access

Detailed competitors of FluidForm Bio

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of FluidForm Bio

The website of FluidForm Bio (fluidformbio.com) receives about 3K visits a month.

  • Monthly visits
    3K

    ▲ 74.5% vs previous month

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as FluidForm Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Fluidform Bio

Premium access

Complete news archive for FluidForm Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about FluidForm Bio

FluidForm Bio was founded in 2017 and raised its 1st funding round 4 years after it was founded.

FluidForm Bio is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.

Michael Graffeo is the CEO of FluidForm Bio, as recorded in our data. They have also founded this company.

FluidForm Bio has 19 employees.

FluidForm Bio was founded in 2017 and is based in Waltham, United States. 3D bioprinting solutions for engineered tissues are developed by the company within the biotechnology sector. FRESH technology is integrated with 3D printing, computational biology, synthetic biology, artificial intelligence, and advanced materials. Tissues are constructed using cells and proteins for applications in research and medical fields.

FluidForm Bio's top competitors include Amyris, AskBio and Ginkgo Bioworks.

FluidForm Bio offers FRESH 3D Bioprinting.

FluidForm Bio has 1 investor. Key investors include HHS.

FluidForm Bio operates through Fluidform, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available